Paroxysmal kinesigenic dyskinesia (PKD) is a heterogeneous movement disorder characterized by recurrent dyskinesia attacks triggered by sudden movement. PRRT2 has been identified as the first causative gene of PKD. However, it is only responsible for approximately half of affected individuals, indicating that other loci are most likely involved in the etiology of this disorder. To explore the underlying causative gene of PRRT2-negative PKD, we used a combination strategy including linkage analysis, whole-exome sequencing and copy number variations analysis to detect the genetic variants within a family with PKD. We identified a linkage locus on chromosome 12 (12p13.32-12p12.3) and detected a novel heterozygous mutation c.956 T>G (p.319 L>R) in the potassium voltage-gated channel subfamily A member 1, KCNA1. Whole-exome sequencing in another 58 Chinese patients with PKD who lacked mutations in PRRT2 revealed another novel mutation in the KCNA1 gene [c.765 C>A (p.255 N>K)] within another family. Biochemical analysis revealed that the L319R mutant accelerated protein degradation via the proteasome pathway and disrupted membrane expression of the Kv1.1 channel. Electrophysiological examinations in transfected HEK293 cells showed that both the L319R and N255K mutants resulted in reduced potassium currents and respective altered gating properties, with a dominant negative effect on the Kv1.1 wild-type channel. Our study suggests that these mutations in KCNA1 cause the Kv1.1 channel dysfunction, which leads to familial PKD. The current study further extended the genotypic spectrum of this disorder, indicating that Kv1.1 channel dysfunction maybe one of the underlying defects in PKD.
Introduction
Paroxysmal kinesigenic dyskinesia (PKD) (OMIM 128200) is a relatively rare movement disorder characterized by childhood onset of transient and recurrent dystonic or choreoathetoid attacks triggered by sudden movement or sudden acceleration or change in direction of movement. PKD is infrequently triggered by other stimuli such as startle, stress, or hyperventilation (1) . The attacks usually present with dystonia, chorea, ballism, athetosis or a combination of these symptoms, which usually lasts from a few seconds to a few minutes. Patients with PKD do not show loss or alteration of consciousness during the attacks. PKD is often associated with infantile convulsions (IC) or convulsions with choreoathetosis (ICCA), demonstrating obvious heterogeneity. Attacks respond well to anticonvulsant therapy, such as low doses of carbamazepine and oxcarbazepine, and usually decrease with age (1, 2) . Unlike secondary PKD, which is caused by multiple sclerosis, head injury, metabolic derangements or cerebral perfusion insufficiency (3), primary PKD can be further classified as familial or sporadic PKD according to hereditary characteristics. Familial PKD is more common, which is usually inherited in an autosomal dominant manner (4) .
Over the past 20 years, three PKD-critical loci, episodic kinesigenic dyskinesias 1 (EKD1) (16p11.2-q12.1), EKD2 (16q13-q22.1), and EKD3, have been identified (5) . In 2011, by combining classic linkage analysis with whole-exome sequencing, our group and other researchers identified the proline-rich transmembrane protein 2 (PRRT2) gene as the first causative gene of PKD (5, 6) . According to recent studies, PRRT2 mutations accounted for $61.5-100% of patients with familial PKD and 11-50% of sporadic PKD cases (7) (8) (9) (10) (11) , suggesting that other genes may be responsible for this syndrome. Recently, genetic advances have led to further in-depth functional studies, greater diagnostic certainty, improved genetic counseling, and individualized precision medical therapeutics (12) . Using linkage analysis and whole-exome sequencing we attempted to identify genes that may be associated with PRRT2-negative PKD.
A vast variety of voltage-gated K þ (Kv) channels play critical roles in setting neuronal excitability, controlling neuronal firing frequencies, shaping action potential waveforms, and modulating neurotransmitter release (13) . The Shaker-related voltagegated K þ channel Kv1.1a subunit, encoded by KCNA1, is mainly located at axon initial segments and presynaptic axon terminals in the central nervous system, particularly in the cerebellum, hippocampus and hypothalamus; this channel is also expressed in juxtaparanodes at nodes of Ranvier in the myelinated nerves of the peripheral nerve system (14) (15) (16) . It is essential for producing a hyperpolarizing effect on the membrane potential and therefore limiting neuronal excitability (16) (17) (18) . Mutations in KCNA1 have a broad phenotypic spectrum, including episodic ataxia 1 (EA1) with or without myokymia, epilepsy, isolated neuromyotonia, EA with hyperthermia or paroxysmal dyspnea, persistent cerebellar dysfunction with cognitive/motor development delay, primary hypomagnesemia, distal lower limb weakness, and isolated cataplexy, among others (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . To date, 34 different disease-related KCNA1 mutations have been identified at 27 sites, with most having a dominant negative effect (19, 21, 29, 30) . However, the specific functional effects of these mutations do not correspond to a particular phenotype, and instead show remarkable heterogeneity. Considering the remarkable phenotypic variability, which may be owing to genetic buffering and/or epigenetic or environmental factors, no obvious genotypephenotype correlations have been established (21, 25) . In this study, using a combination strategy of linkage analysis, whole-exome sequencing and copy number variation (CNV) analysis, we identified two heterozygous KCNA1 mutations in unrelated pedigrees that may be novel genetic causes of familial PKD. We also expressed mutated KCNA1 plasmids in HEK293 cells and performed biochemical and electrophysiology studies. Biochemical analysis revealed that the L319R mutation impaired protein stability and disrupted membrane expression of the channel. Electrophysiological examinations showed that both the L319R and N255K mutants resulted in reduced current amplitude and respective altered gating properties, with a dominant negative effect on the Kv1.1 wild-type (WT) channel. Our study suggests that pathogenic mutations in KCNA1 are responsible for familial PKD, indicating that Kv1.1 channel dysfunction maybe one of the underlying defects in PKD.
Results
The clinical characteristics of Family 1 with PKD Family 1 is a fourth-generation Han Chinese family that includes eight affected individuals (Fig. 1A, Family 1) . Detailed clinical characteristics are summarized in Table 1 . The proband (individual IV-6) was a 19-year-old girl who suffered from episodic dyskinesia attacks in partial (especially the left side) or bilateral limbs at the age of 15 years. Dystonic posture, which lasted for <10 s, was usually precipitated by sudden movements, intention to move, or stress and occurred up to more than 20 times a day. During the attack, dysarthria was also noticed, suggesting bulbar involvement. Neither loss nor impairment of consciousness was observed in the attacks. The interictal clinical examination of the proband was normal. In particular, there were no signs of ataxia, myokymia, seizure, dizziness or diplopia. No abnormal laboratory test results (including magnesium in the blood) were observed, and both electroencephalograms (EEG) and magnetic resonance imaging (MRI) of the brain were normal. Electromyography of the left deltoid, left abductor pollicis brevis (APB), left anteriortibialis (AT) and right peroneus longus muscles revealed no myokymia or other abnormalities. More importantly, symptoms of the movement disorder could be significantly improved by oxcarbazepine treatment (400 mg/day). According to the new diagnostic criteria for PKD (1), this girl was diagnosed with idiopathic PKD.
The family also presented a wide spectrum of clinical heterogeneity. In an additional three affected individuals (II11, III14 and III23) in Family 1, similar attacks of paroxysmal movement disorders accompanied by a history of seizures were also described. The onset ages for these individuals varied from childhood to adolescence, and remission ages were from approximately 25 to 37 years. The seizure complaint was mainly based on a retrospective description and witness account of consciousness loss. The interictal EEG recording of III14 showed extensive mild abnormality without obvious epileptic discharges. In III14, the symptoms of both movement disorder and seizure could be significantly improved by oxcarbazepine treatment. III23 was prescribed 200 mg/day of carbamazepine, and this individual's symptoms also improved. In an additional four affected individuals (I1, II6, III10 and III16) in Family 1, the paroxysmal dyskinesia (PxDs) was characterized by episodic dystonia attacks of the limbs, which lasted for $10 min and were usually triggered by stress and anger. The onset and remission ages were approximately 20 and 40 years, respectively. Five of the eight affected individuals also suffered from migraines without aura. However, clinical abnormalities, such as ataxia, neuromyotonia, myokymia, tremor, dizziness or diplopia were never observed clinically in all affected individuals. Blood samples were collected from seven affected individuals (a sample from I-1 was not available) and twelve unaffected individuals from the same family.
Identification of a novel missense mutation in KCNA1 causative for familial PKD (Fig. 1A and C) . The III16 individual without the variant, who suffered from similar PxDs with normal neurological (CT and EMG) investigations, was attributed to the phenocopy phenomenon and categorized as having psychogenic PxDs after detailed inspection and comprehensive analysis. The identified mutation in KCNA1 caused substitution of a highly conserved non-polar leucine to a positively charged arginine at position 319 (L319R) (Fig. 1D) , which was absent from 8000 control chromosomes of Chinese origin and from the publicly available databases (the Genome Aggregation Database, 6500 Exomes Sequencing Project and 1000 Genomes Project). This mutation was predicted to be deleterious to the protein structure and function according to SIFT, PolyPhen-2, and MutationTaster analysis, which supported its pathogenicity. The predicted amino acid topology of Kv channels showed 6 transmembrane-spanning a-helical segments (i.e. S1-S6), with the S4 segment acting as a voltage sensor and a hydrophobic pore region between S5 and S6. The newly identified L319R mutation is located in the intracellular S4-S5 linker at the interface of transmembrane domain S5 and the cytoplasm (Fig. 1 E) (31); this region is highly conserved and is important for electromechanical coupling in Kv channels (32, 33) . According to the standards and guidelines for the interpretation of sequence variants by ACMG (34), the identified novel variant was categorized as 'likely pathogenic' owing to an evidence criterion of two moderate evidences (PM1, 2) and !2 supporting evidences (PP1-3) that a variant is pathogenic.
Mutation screening of KCNA1 in additional PKD cases lacking mutations in PRRT2
Subsequently, we performed whole-exome sequencing in an additional 57 cases who were clinically diagnosed with PKD but lacked mutations in PRRT2, including 11 probands from small families and 46 sporadic cases, to detect the potential causative mutation in KCNA1. However, none of these PKD patients exhibited additional mutations in KCNA1. In addition, we also did not identify other deleterious mutations in known paroxysmal movement disorders-related genes, particularly other potassium channels, such as KCNQ2 and KCNQ3 related to BFNIS. At the same time, by whole-exome sequencing, our collaborators found another novel variant (NM_000217, c.765 C>A, p.255 N>K) in KCNA1 from a family with typical PKD lacking mutations in PRRT2. This variant was cosegregated with disease and re-verified by Sanger sequencing (35) . The newly identified mutation was also absent from 8000 control chromosomes of Chinese origin and from the publicly available databases (the Genome Aggregation Database, 6500 Exomes Sequencing Project and 1000 Genomes Project) and was consistently predicted to be pathogenic by in silico prediction tools (SIFT, PolyPhen-2 and MutationTaster). The Kv1.1 mutant N255K changed the evolutionarily conserved, neutral asparagine into a positively charged lysine at position 255 in the third transmembrane segment (S3) close to the voltage sensor ( Fig. 1D and E) where a different missense variation determined to be pathogenic had previously been related to hypomagnesemia (N255D) (24) . According to the ACMG guidelines (34), the second variant was categorized as 'likely pathogenic' owing to !3 moderately pathogenic pieces of evidences (PM1, 2 and 5). and the L319R mutation is located on the loop between S4 and the pore-forming region (S5 and S6).
L319R accelerates protein degradation via the proteasome pathway and disrupts membrane expression of the Kv1.1 WT channel
Since Kv1.1 is a potassium channel that should be localized to the cell membrane, we examined membrane-localized Kv1.1 using cell surface biotinylation. Our results showed that the L319R mutation reduced membrane Kv1.1 localization compared with Kv1.1 WT (Fig. 2A) . However, the membrane/total ratio of Kv1.1 with the L319R mutation was not changed compared with that of Kv1.1 WT channel, indicating that L319R disrupted membrane localization, but did not appear to be defective in its membrane trafficking efficiency (Fig. 2B-D) . As we have ruled out that Kv1.1 L319R affected trafficking efficiency, we speculated that the observed decreased expression of Kv1.1 in the whole lysate maybe caused by enhanced degradation of the L319R mutation channel. Thus, we performed a cycloheximide (CHX) pulse chase assay to determine the protein stability of the mutant Kv1.1. Protein degradation of Kv1.1 was accelerated by the L319R mutation but not by the N255K mutation (Fig. 2E) . Subsequently, inhibiting proteasomal activity with MG132 stabilized the level of Kv1.1 L319R, making its expression insignificantly different from that of the WT version (Fig. 2E) . These results suggested that the decreased membrane fraction of Kv1.1 L319R was associated with its enhanced degradation via the proteasome pathway (UPS). However, membrane transportation of the N255K mutant was not significantly affected ( Fig. 2A-D ).
L319R and N255K interfere with Kv1.1 current density, voltage-dependent gating and activation/deactivation kinetics with dominant negative effect Since Kv1.1 functions as a potassium-selective channel to maintain the electrochemical gradient, we performed whole cell patch clamp analysis to determine whether the two Kv1.1 mutants were able to maintain channel function. The currents of cells transfected either with Kv1.1 WT, L319R or N255K alone or Kv1.1 WT and L319R or WT and N255K simultaneously were recorded. The channels of cells transfected with Kv1.1 WT displayed typical delayed rectifying currents in response to a depolarizing step from À80 to þ40 mV, in 10 mV increments, from a holding potential of À80 mV. In contrast, the K þ currents of cells transfected with either the L319R or N255K mutants showed significantly smaller peak current densities compared with that of cells transfected with Kv1.1 WT (WT, 203.2 6 8.45 pA/pF; L319R, 25.86 62.66 pA/pF, P < 0.001; N255K, 33.54 6 3.60 pA/pF, P < 0.001) (Fig. 3A-C) . Similarly, cells in which Kv1.1 WT and respective mutant versions were co-expressed also showed reduced current densities, which reflected the heterozygous presentations among patients (WT: L319R, 62.90 6 2.96 pA/pF, P < 0.001; WT: N255K, 78.54 6 2.71 pA/pF, P < 0.001) and indicated that both mutants exerted a dominant-negative effect on WT channel activity (Fig. 3C) .
To characterize the voltage dependence of activation, tail currents were recorded upon repolarization to À80 mV following prepulse voltage steps. Analysis of the activation curves revealed that both mutants caused a significant depolarizing shift in the V 1/2 of the voltage dependence of channel activation ($17.5 mV for L319R and $37.5 mV for N255K). Cells in which WT: L319R and WT: N255K were co-expressed also exhibited a similar depolarizing shift of V 1/2 , with shifts of $12 and $24 mV, respectively ( Fig. 4A and B) . The slope factor k for both mutant channels was not significantly altered when compared with that of the Kv1.1 WT channel, indicating that the steepness of voltage dependence was not affected by both mutants (Supplementary Table S1 ).
To determine the kinetics of activation, activation time constants were derived from one-exponential fits of the rising phase of test currents. At a given potential, Kv1.1 L319R activated $4 times and N255K activated $3.5 times, which were both slower than Kv1.1 WT (Fig. 4C and D) . When comparing the time constant s V1=2 determined at V 1/2 , L319R yielded significant effects on the gating parameters of Kv1.1 channel. However, the time constant s V 1=2 between N255K and WT was not significantly different, indicating that the slower s of N255K may be solely owing to a shift in the voltage dependence of activation (Supplementary Table S1 ).
The deactivation kinetics of the Kv1.1 L319R channel, which were determined from tail currents, demonstrated deactivation $0.5 times faster than that of the Kv1.1 WT channel, indicating that L319R accelerated Kv1.1 channel deactivation. Meanwhile, N255K impeded the deactivation kinetics by $1.5 times (Fig. 4E and F) . Similarly, neither the s V 1=2 of the L319R nor the N255K channel was altered compared with that of the WT channel (Supplementary Table S1 ).
To ascertain whether both mutations affect inactivation, voltage dependence of inactivation was determined by plotting the relative amplitudes of the elicited outward currents at þ30 mV after 2-s conditioning prepulses to potentials between -80 and þ30 mV. Steady-state inactivation curves demonstrated a $21.5-mV positive shift in the L319R channel and $22-mV negative shift in the N255K channel when compared with WT ( Fig. 4G and H) . The slope factor k was not significantly changed in either mutant channel (Supplementary Table S1 ).
Thus, combined with the strong evidence of pathogenicity (PS3), the two novel identified mutations in KCNA1 could both be classified as "pathogenic" and considered to be responsible for this familial disorder.
Discussion
In the present study, two novel mutations in KCNA1 were identified in patients with familial PKD, further expanding the genotypic spectrum of this disorder. Both identified mutants had significant dominant-negative effects on the biophysical properties of the Kv1.1 channel. To the best of our knowledge, these are the first two KCNA1 mutations detected in familial PKD.
Family 1 in this study had coexistent PKD, PxDs, seizures and migraines. Moreover, epileptic seizures were more common in the individuals affected by typical PKD in this family. Recently, phenotypic overlap and clinical heterogeneity were also found among other genes that cause paroxysmal disorders. Mutations in PRRT2 were associated with PKD, IC, febrile seizures, hemiplegic migraine or EA; and mutations in SLC2A1 occurred in paroxysmal exercise-induced dyskinesia, PKD, paroxysmal non-kinesigenic dyskinesia, EA and myotonia (36) (37) (38) (39) , indicating the existence of a common pathophysiological basis among these paroxysmal disorders. Individual III16 in Family 1, who lacked the L3I9R mutation, was diagnosed with psychogenic PxDs, which has a very high within-subject variability for attack phenomenology, duration and frequency, without any obvious organic or genetic abnormalities (40, 41) . Although a positive family history may suggest organic or genetic disease, a 38-year-old woman with psychogenic chorea from a family with Huntington's disease showed similar phenomenology in her affected family members, supported by her normal CAG repeats in the HTT gene (42) , which might also help explain the situation in Family 1 described here. Kv1.1 plays an integral role in modulating neuronal excitability through efficient repolarization of the membrane following an action potential, thereby preventing the occurrence of repetitive discharges (43) . In both the central and peripheral nervous systems, different heterotetramers of mutant Kv1.1a with WT Kv1.1a subunits, auxiliary Kvb subunits and other isoforms of the Kv1 subfamily could exert respective functional characteristics of channels, resulting in a variety of clinical manifestations (44) . In this study, we identified two novel heterozygous KCNA1 mutations from two unrelated PKD families, indicating a novel cause of familial PKD. The potential relationship between PKD and Kv1.1 dysfunction has also been supported by previous studies in which one affected individual from an EA1 family with E325D mutation and two patients in an EA1 family with R324T mutations had been diagnosed with PKD (with or without EA) (45, 30) .
Considering the rapid protein degradation and unaltered membrane transportation efficiency of the L319R mutant, the decrease of Kv1.1 membrane expression caused by L319R was owing to impaired protein stability. Moreover, L319R-associated degradation was significantly blocked by treating cells with protease inhibitor, indicating that the mutant Kv1.1 is mainly degraded by the UPS. Similarly, a recent study showed that an I262T mutation, identified in patients with EA, enhanced protein degradation but did not alter Kv1.1 membrane trafficking efficiency. These authors also mentioned that the mechanism by which I262T alters Kv1.1 channel function could include disabling Kv1.1 channel formation (46) . Our electrophysiological studies demonstrated that L319R reduced Kv1.1 channel current amplitude by $87%, positively shifted the voltage dependence of activation and inactivation, and slowed activation and accelerated deactivation kinetics compared with WT Kv1.1. The reduced current amplitude of the L319R mutant channel may also be ascribed to the failure of hydrophobic packing between two transmembrane helices, which is important in coupling the voltage sensor to pore opening (32, 33) . Based on a previous study and our results, there are three possible explanations for the pathogenesis of the L319R mutation, including the following: (i) L319R accelerates WT degradation resulting in less Kv1.1 channel protein expression on the cell membrane, (ii) low dose L319R dissembles the channel heterotetramers and (iii) L319R disrupts hydrophobic packing. Taken together, the L319R mutant may be associated with rapid degradation and disruption of channel formation, thereby manifesting reduced surface expression and a smaller K þ current amplitude.
Cell surface biotinylation studies have also shown that the expression levels at the plasma membrane were comparable between the mutant N255K and WT Kv1.1. Thus, the change in amino acid had no significant effect on channel surface expression. However, the mutant N255K had a clear effect on channel activity as we demonstrated that K þ current amplitude recorded in the N255K mutant channel was reduced to $16.5% of Kv1.1 WT. In addition, the N255K mutant channel displayed a positive shift in voltage dependence of activation, a negative shift in steady-state inactivation, and slower activation and deactivation kinetics. In line with this, a previous study demonstrated that the asparagine at position 255 in Kv1.1 is quite essential for normal voltage dependence and kinetics of channel gating. Substitution of N255 with different hydrophilic or hydrophobic amino acids did not alter membrane expression, but resulted in significantly altered channel activity, voltage dependence and kinetics of the Kv1.1 channel (47) . It has been demonstrated that negatively charged clusters in the S1, S2 and S3 segments, together with the positive charges in S4, are involved in the opening and closing of Kv1 channels by forming stabilizing hydrogen bonds (48) . On one hand, since positively charged lysine is always fully protonated, this increases electrostatic affinity between hydrogen bond donor and acceptor making position 255 more polarized. On the other hand, we suggest that the change in charge of the amino acid at residue 255 could also contribute to channel dysfunction. Therefore, the detrimental effect of N255K on K þ current amplitude and channel function was probably owing to the following: (i) the influence on the formation of stabilizing hydrogen bonds and (ii) altered amino acid residue electrostatic characteristics. Thus, to some extent, both the L319R and N255K mutants showed comparable defects in channel function, resulting in declined efflux of K þ ions, which are expected to increase neuronal excitability and enhance duration of action potentials. Thus, these mutants share similar pathological changes in PKD pathogenesis and cause typical clinical manifestations of PKD. Kv1.1 interacts with Syntaxin-1, which is a component of the Soluble NSF Attachment Protein REceptor (SNARE) core complex, and plays an essential role in synaptic exocytosis and neurotransmission (49) . Thus, the dual functionality of the Kv channel regulating release emerges; one function is hyperpolarization of the membrane potential and the other is direct facilitation of release through its interactions with Syntaxin-1. A recent study also showed that the PRRT2 protein is an essential component of Ca 2þ -dependent neurotransmitter release through the SNARE complex (50) . It is possible that in PKD, the neurotransmitter release is disturbed by PRRT2 or Kv1.1 dysfunction, leading to network instability/hyperexcitability and thereby to paroxysmal disorders. The shared mechanisms also support the view that PKD is a kind of synaptopathy.
Meanwhile, increasing evidence from clinical, neuroimaging, electrophysiological and animal model studies have demonstrated the overlap in pathology between dystonia and ataxia (51) . The cerebellum is interconnected with the cerebral cortex and the basal ganglia (52, 53) . Neurochemical evidence has demonstrated the existence of communication between the basal ganglia and cerebellum via some subcortical connections (54) . In fact, a common phenomenon among many different forms of human PxDs is enhanced cortical excitability or impaired cortical inhibition (55) . Cortical excitability is regulated by both the basal ganglia and cerebellum, with some evidence showing that these two structures exert opposing influences (56) (57) (58) . Thus, the influences of the basal ganglia and cerebellum may converge upon cortical excitability as a common final pathway for paroxysmal dystonic movement. Our study also indicated that functional abnormalities related to the cerebellum may participate in the pathophysiology of PKD.
Taken together, these findings extend the genotypic spectrum of PKD and further establish the association of PKD with other paroxysmal disorders, including EA and epilepsy. Beyond that, PKD may be associated with increased cortical excitability resulting from cerebellum dysfunction and is also a synaptopathy. Understanding the potential shared pathogenesis and mechanism network will provide new targets for drug development. Based on the results of our study, KCNA1 genetic analysis should be performed in PRRT2-negative patients with PKD, especially familial cases. Further investigation s with more patients will be necessary to highlight the frequency of KCNA1 mutation and elucidate the significance of this gene in PKD pathogenesis.
Materials and Methods

Standard protocol approvals, registrations, and patient consents
This study was approved by the ethical review board of Xiangya Hospital, Central South University, Changsha, China. All participants or their legal guardians provided written informed consent for genetic investigation.
Families and patients
A Chinese Han PKD pedigree with autosomal dominant inheritance was included and named as Family 1 (seven patients and twelve unaffected individuals in this family were from The First Affiliated Hospital of Harbin Medical University). An additional 58 patients, including 12 familial probands and 46 sporadic cases, were also enrolled (57 from Xiangya Hospital and 1 family from Rui Jin Hospital). Patients with PRRT2 mutations were not included in this study. All patients were recruited after being evaluated by two or more experienced neurologists and clinical geneticists. The diagnosis of PKD was determined according to Bruno's criteria (1). Genomic DNA was prepared from peripheral blood according to standard procedures as previously described (5) .
SNP array analysis and whole-exome sequencing in patients with PKD
The proband of Family 1 and the additional 58 patients had previously gone undergone PRRT2 mutation screening, and pathogenic mutations in this gene were excluded. Genome-wide CNV analysis was performed using the Illumina HumanCytoSNP-12 BeadChip (Illumina, San Diego, CA, USA) for the proband of Family 1. Data from the images were analyzed using the cnvPartition Plug-in v3.1.6 for GenomeStudio (Illumina). Pathologically or clinically significant CNVs were screened according to the following criteria: (i) relatively large size (more than 1 Mb), (ii) overlapping with or interrupting genes or hotspots (especially paroxysmal movement disorders-and epilepsy-related genes) and (iii) rare CNVs. A genome-wide linkage analysis was performed in seven affected and nine unaffected family members from Family 1 using the Illumina humanomnizhonghua-8v1-1 (Illumina). The error-checking option in Merlin was used to verify the genotype data. Multipoint LOD scores were calculated using Merlin (59) . LOD score calculations were performed assuming an autosomal dominant pattern of inheritance, with a disease allele frequency of 0.0001 and a penetrance value of 0.950. Whole exome sequencing was performed on chosen patients using the SureSelectXT Human All Exon Kit (V5; Agilent Technologies, Santa Clara, CA, USA) and sequenced on the Illumina HiSeq X system (Illumina) with 150-bp paired-end reads. Alignment to the human genome assembly hg19 (GRCh37) was carried out followed by recalibration and variant calling. Exome data processing, variant calling, and variant annotation were performed as previously described (5, 60) . The candidate variants were further confirmed using Sanger sequencing in all available family members.
Cells and plasmids
HEK293 cells were obtained from ATCC and maintained as recommended by the provider. The KCNA1 coding sequence (NM_000217) was PCR amplified from HEK293 cDNA using the following primers: forward: ccgCTCGAGatgacggtgatgtct and reverse: cggGGATCCttaaacatcggtcag. The KCNA1 product was subcloned into the Xho1 and BamH1 sites of pEGFP-C1. KCNA1 mutants were generated using the QuikChange site-directed Mutagenesis Kit from Strategene (La Jolla, USA) according to the manufacturer's instructions. Site mutation primers for the KCNA1 mutants were as follows: L319R forward: AAAAACATCATGAAaTTCATAGA, L319R reverse: CAATGTCTATGAAtTTCATGATG, N255K forward: AAAAACATCATGAAaTTCATAGA and N255K reverse: CAATGT CTATGAAtTTCATGATG. WT and mutant clones were sequenced to verify the presence of the mutations.
Antibodies and chemicals
Anti-GFP monoclonal antibody was purchased from Labome (632381, Princeton, USA). Anti-CD71 monoclonal antibody was purchased from Cell Signalling Technology (13113, Danvers, USA). Anti-b-actin antibody was purchased from Sigma-Aldrich (St. Louis, USA). CHX and MG132 were purchased from SigmaAldrich. . Twenty micrograms of the whole lysate were saved as input. The biotinylated proteins (cell membrane fraction) were precipitated using NeutrAvidinagarose beads (Thermo Scientific) and boiled in Laemmli sample buffer for 10 min. Proteins were analyzed by immunoblot; Kv1.1 was detected by anti-GFP antibody (1:1000), and CD71 was detected by anti-CD71 antibody (1:1000) as a membrane protein control. The whole lysates were detected by anti-GFP antibody and anti-b-actin antibody as a loading control. Protein quantitation was completed using ImageJ software (NIH, Bethesda, USA).
Biotinylation of cell surface proteins
CHX pulse chase experiments
HEK293 cells were transfected with either Kv1.1 WT or its mutants followed by CHX (10 lM) or along with MG132 (10 mM) treatment for 0, 0.5, 1, 2 or 4 h. Protein levels of Kv1.1 were determined by western blot using anti-GFP antibody and anti-bactin antibody as a loading control.
Electrophysiology
Whole-cell patch clamp recordings were performed 24 h after transfection to assess potassium currents at room temperature. The extracellular solution contained 124 mM NaCl, 3 mM KCl, 1.25 mM NaH 2 PO 4 , 2 mM MgCl 2 , 2 mM CaCl 2 , 26 mM NaHCO 3 and 10 mM C 6 H 12 O 6, pH ¼ 7.4, 305 mOsm. Pipette resistance was 4-6 MX after being filled with intracellular solution, which contained 140 mM K-gluconate, 10 mM HEPES, 0.2 mM EGTA, 0.2 mM NaCl, 2 mM Mg 2 ATP and 2 mM Na 3 GTP, pH ¼ 7.4, 296 mOsm. The holding potential was -80 mV. Compensation of series resistance, subtraction of linear leakage and capacity currents were used. Data were acquired at 10 kHz and filtered at 2 kHz. Analysis of data was performed using Clampfit software (Molecular Devices, CA, USA). Current densities were obtained by normalizing the current amplitude to the cell membrane capacitance.
Statistical analysis
Statistical analysis was performed using Prism 5 software (GraphPad, La Jolla, USA). Statistical significance between multiple groups was evaluated using one-way ANOVA followed by Tukey's test. All error bars indicate SEM. The quantitation was performed in a double-blind manner.
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